Cancer Development and Progression in Patients with Heart Failure.

IF 3.8 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Current Heart Failure Reports Pub Date : 2024-12-01 Epub Date: 2024-09-28 DOI:10.1007/s11897-024-00680-y

Katharina Seuthe, Felix Simon Ruben Picard, Holger Winkels, Roman Pfister

{"title":"Cancer Development and Progression in Patients with Heart Failure.","authors":"Katharina Seuthe, Felix Simon Ruben Picard, Holger Winkels, Roman Pfister","doi":"10.1007/s11897-024-00680-y","DOIUrl":null,"url":null,"abstract":"Purpose of review: The co-occurrence of heart failure (HF) and cancer represents a complex and multifaceted medical challenge. Patients with prevalent cardiovascular disease (CVD), particularly HF, exhibit an increased risk of cancer development, raising questions about the intricate interplay between these two prevalent conditions. This review aims to explore the evolving landscape of cancer development in patients with HF, shedding light on potential mechanisms, risk factors, and clinical implications.Recent findings: Epidemiological data suggests higher cancer incidences and higher cancer mortality in HF patients, which are potentially more common in patients with HF with preserved ejection fraction due to related comorbidities. Moreover, recent preclinical data identified novel pathways and mediators including the protein SerpinA3 as potential drivers of cancer progression in HF patients, suggesting HF as an individual risk factor for cancer development. The review emphasizes preliminary evidence supporting cancer development in patients with HF, which offers several important clinical interventions such as cancer screening in HF patients, prevention addressing both HF and cancer, and molecular targets to treat cancer. However, there is need for more detailed understanding of molecular and cellular cross-talk between cancer and HF which can be derived from prospective assessments of cancer-related outcomes in CV trials and preclinical research of molecular mechanisms.","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":" ","pages":"515-529"},"PeriodicalIF":3.8000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11511767/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Heart Failure Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s11897-024-00680-y","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/28 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: The co-occurrence of heart failure (HF) and cancer represents a complex and multifaceted medical challenge. Patients with prevalent cardiovascular disease (CVD), particularly HF, exhibit an increased risk of cancer development, raising questions about the intricate interplay between these two prevalent conditions. This review aims to explore the evolving landscape of cancer development in patients with HF, shedding light on potential mechanisms, risk factors, and clinical implications.

Recent findings: Epidemiological data suggests higher cancer incidences and higher cancer mortality in HF patients, which are potentially more common in patients with HF with preserved ejection fraction due to related comorbidities. Moreover, recent preclinical data identified novel pathways and mediators including the protein SerpinA3 as potential drivers of cancer progression in HF patients, suggesting HF as an individual risk factor for cancer development. The review emphasizes preliminary evidence supporting cancer development in patients with HF, which offers several important clinical interventions such as cancer screening in HF patients, prevention addressing both HF and cancer, and molecular targets to treat cancer. However, there is need for more detailed understanding of molecular and cellular cross-talk between cancer and HF which can be derived from prospective assessments of cancer-related outcomes in CV trials and preclinical research of molecular mechanisms.

查看原文本刊更多论文

心力衰竭患者的癌症发展与恶化

审查目的：心力衰竭（HF）与癌症并发是一项复杂而多方面的医学挑战。心血管疾病（CVD），尤其是心力衰竭（HF）患者罹患癌症的风险增加，从而引发了这两种常见疾病之间错综复杂的相互作用的问题。本综述旨在探讨心房颤动患者罹患癌症的演变情况，揭示潜在的机制、风险因素和临床影响：流行病学数据表明，心房颤动患者的癌症发病率和死亡率较高，而在射血分数保留的心房颤动患者中，由于相关合并症，癌症发病率和死亡率可能更高。此外，最近的临床前数据发现，包括蛋白 SerpinA3 在内的新型通路和介质是导致心房颤动患者癌症进展的潜在因素，这表明心房颤动是癌症发展的一个个体风险因素。综述强调了支持高血脂患者癌症发展的初步证据，这提供了一些重要的临床干预措施，如高血脂患者的癌症筛查、针对高血脂和癌症的预防以及治疗癌症的分子靶点。然而，还需要更详细地了解癌症与高血压之间的分子和细胞交叉作用，这可以从慢性病试验中癌症相关结果的前瞻性评估和分子机制的临床前研究中获得。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Heart Failure Reports Medicine-Emergency Medicine

CiteScore

5.30

自引率

0.00%

发文量

期刊介绍： This journal intends to provide clear, insightful, balanced contributions by international experts that review the most important, recently published clinical findings related to the diagnosis, treatment, management, and prevention of heart failure. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as investigative, pharmacologic, and nonpharmacologic therapies, pathophysiology, and prevention. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.